[1]李现成,屈 凯,王 宇,等.中医药治疗腹膜透析肾性贫血新策略[J].陕西中医,2023,(4):538-540,544.[doi:DOI:10.3969/j.issn.1000-7369.2023.04.030]
　LI Xiancheng,QU Kai,WANG Yu,et al.New strategy of TCM treatment of peritoneal dialysis renal anemia[J].,2023,(4):538-540,544.[doi:DOI:10.3969/j.issn.1000-7369.2023.04.030]
点击复制

中医药治疗腹膜透析肾性贫血新策略
分享到：

《陕西中医》[ISSN:1000-7369/CN:61-1281/TN]

卷:
期数:
2023年4期
页码:
538-540,544
栏目:
综 述
出版日期:
2023-04-05

文章信息/Info

Title:
New strategy of TCM treatment of peritoneal dialysis renal anemia
作者:
李现成; 屈 凯; 王 宇; 赵亚峰; 程小红; 于小勇
(陕西省中医医院,陕西 西安 710003)
Author(s):
LI Xiancheng; QU Kai; WANG Yu; ZHAO Yafeng; CHENG Xiaohong; YU Xiaoyong
(Shaanxi Hospital of Traditional Chinese Medicine,Xi'an 710003,China)
关键词:
肾性贫血;  慢性肾脏病;  炎性因子;  腹膜透析;  残余肾功能
Keywords:
Renal anemia;  Chronic kidney disease;  Inflammatory factor;  Peritoneal dialysis;  Residual renal function
分类号:
R 556.9
DOI:
DOI:10.3969/j.issn.1000-7369.2023.04.030
文献标志码:
A
摘要:
腹膜透析(PD)作为肾脏替代治疗的主要方法之一,被越来越多的终末期肾病患者所接受。肾性贫血作为慢性肾脏病主要并发症之一,PD后更为常见。中医药治疗肾性贫血疗效确切,现通过检索中医药治疗PD肾性贫血的文献,进行系统评价,总结目前中医药治疗PD肾性贫血的各种机制,结合西医治疗肾性贫血进展,为中医药治疗PD肾性贫血提供新策略。
Abstract:
As one of the main methods of renal replacement therapy,PD has been accepted by more and more patients with ESRD.Renal anemia,one of the main complications of CKD,is more common after PD.Traditional Chinese medicine is effective in the treatment of renal anemia,by searching the literature on the treatment of PD renal anemia with traditional Chinese medicine,this paper conducted a systematic review,summarized the various mechanisms of the treatment of PD renal anemia with traditional Chinese medicine,combined with the progress of western medicine in the treatment of renal anemia,and provided a new strategy for the treatment of PD renal anemia with traditional Chinese medicine.

参考文献/References:

[1] Collaboration G.Global,regional,and national burden of chronic kidney disease,1990-2017:A systematic analysis for the global burden of disease study 2017[J].Lancet,2020,395(10225):709-733.
[2] 梁琛瑜,王万州,马 麟,等.大气NO2长期暴露与中国成人慢性肾脏病的关联:基于中国慢性肾脏病流行病学调查[J].环境与职业医学,2021,38(6):566-572.
[3] 中国医师协会肾脏内科医师分会,中国中西医结合学会肾脏疾病专业委员会,国家肾病专业医疗质量管理与控制中心.自动化腹膜透析中国专家共识[J].中华医学杂志,2021,101(6):388-389.
[4] Reszke R,Szepietowski JC.End-stage renal disease chronic itch and its management[J].Dermatologic Clinics,2018,14(36):277.
[5] Astor BC,Muntner P,Levin A,et al.Association of kidney function with anemia:The third national health and nutrition examination survey(1988-1994)[J].Archives of Internal Medicine,2002,12(162):1401-1402.
[6] 喻 影.慢性肾脏病3～5期(非透析)患者肾性贫血的相关因素分析及中医证型分布规律研究[D].天津:天津中医药大学,2020.
[7] 陈孟华,田 娜.腹膜透析患者的贫血诊治现状[J].中国血液净化,2020,19(9):581-582.
[8] 王洪霞,杨丛旭,张 昱.影响腹膜透析患者血红蛋白水平的相关因素及中医辨证分析[J].世界中西医结合杂志,2010,5(7):600-602.
[9] Verdalles U,Abad S,Vega A,et al.Factors related to the absence of anemia in hemodialysis patients[J].Blood Purification,2011,32(1):69-74.
[10] 中华医学会肾脏病学分会肾性贫血诊断和治疗共识专家组.肾性贫血诊断与治疗中国专家共识(2018修订版)[J].中华肾脏病杂志,2018,34(11):860.
[11] 中华医学会肾脏病学分会.重组人促红细胞生成素在肾性贫血中合理应用的专家共识[J].中国血液净化,2007,6(8):440-443.
[12] Elder SJ,Pisoni RL,Akizawa T,et al.Mineral metabolism and haemoglobin concentration among haemodialysis patients in the dialysis outcomes and practice patterns study(DOPPS)[J].Nephrology Dialysis Transplantation,2020,20(5):927-935.
[13] Nishihara Y,Miyahara M,Utsumi K.Effects of tetrachlorobiphenyls on the osmotic fragility and shape of human erythrocytes[J].Cell Structure and Function,2008,6(4):347-356.
[14] 窦涪琳,王杨威,崔文鹏,等.微炎症状态与肾性贫血[J].中国血液净化,2016,15(3):145-147.
[15] 李 萍,陈孜瑾,蒋钻红,等.维持性血液透析患者血浆铁调素水平及其影响因素分析[J].中国血液净化,2017,16(1):30-33.
[16] Hirobumi A,Junya H,Mie WA.Indoxyl glucuronide,a protein-bound uremic toxin,inhibits hypoxia-inducible factor?Dependent erythropoietin expression through activation of aryl hydrocarbon receptor[J].Biochemical & Biophysical Research Communications,2018,2(504):538-541.
[17] 孙丽萍,周龙珍,董一民.促红细胞生长素联合蔗糖铁治疗血液透析患者肾性贫血疗效观察[J].陕西医学杂志,2013,42(7):889-890.
[18] Begum S,Latunde-Dada GO.Anemia of inflammation with an emphasis on chronic kidney disease[J].Nutrients,2019,11(10):2424.
[19] 李 芸,傅淑霞.红细胞寿命缩短与肾性贫血[J].临床荟萃,2009,24(2):180-181.
[20] 沈海燕,刘孝琴.肾性贫血机制和治疗的研究进展[J].现代医药卫生,2022,38(1):81-85.
[21] 陈晓农,高琛妮.肾性贫血的诊治进展[J].内科理论与实践,2021,16(1):10-11.
[22] 刘兴国,付明洁,曹繁华,等.益肾养血扶正膏治疗肾性贫血的临床研究[J].陕西中医,2016,37(8):1025-1026.
[23] Zhang D,Zheng H,Xu P.Influence of peritonitis on gastrointestinal function of patients with continuous ambulatory peritoneal dialysis[J].Hong Kong Journal of Nephrology,2015,17(2):127.
[24] 杜义斌,陶尚成.持续性不卧床腹膜透析并发消化功能紊乱的中医治疗观察[J].中国中西医结合肾病杂志,2002,3(1):32-33.
[25] 边红萍,刘光珍.中药治疗维持性腹膜透析患者的临床研究[J].光明中医,2012,27(3):611-613.
[26] 江 燕,盛梅笑,宋 欢,等.运脾强生方提高腹膜透析患者生存质量的疗效观察[J].南京中医药大学学报,2013,6(1):524.
[27] 黄雪霞,吴金玉,伍朝春.腹透消食汤治疗腹膜透析患者胃肠道功能紊乱症的临床观察[J].四川中医,2005,23(6):37-39.
[28] 何小泉.补气祛瘀泄浊中药联合复方α-酮酸对维持性腹膜透析患者肾功能及营养指标的影响[J].现代中西医结合杂志,2018,27(11):1172-1174,1178.
[29] 毕洪英,杨占华.腹膜透析患者厌食症的中医治疗[J].中国初级卫生保健,2007,21(4):76.
[30] 黄 琳,庞 捷,李锦山,等.补肾祛毒丸治疗维持性腹膜透析患者营养不良疗效观察[J].海南医学,2016,27(22):3634-3637.
[31] 范 伟,林 娜,胡 路,等.健脾益肾化瘀泄浊法对腹膜透析营养不良患者的影响[J].河南中医,2018,38(11):1715-1719.
[32] 邓 波,胡 亮.扶肾颗粒治疗腹膜透析肠功能障碍疗效评价[J].医药界,2020,9(6):2.
[33] John MM,Gupta A,Sharma R,et al.Impact of residual renal function on clinical outcome and quality of life in patients on peritoneal dialysis[J].Saudi J Kidney Dis Transpl,2017,28(1):30-35.
[34] 束永兵,文 艳.益肾活血方对腹膜透析患者残余肾功能的影响[J].陕西中医,2021,42(4):486-488.
[35] 何敏尔,朱声宏.腹膜透析联合中药保留灌肠治疗慢性肾功能衰竭16例临床研究[J].江苏中医药,2010,42(8):27-28.
[36] 沈伟钢,张 菁.小剂量腹膜透析加中药保留灌肠治疗慢性肾功能衰竭16例临床观察[J].中国中医药科技,2009,16(6):694.
[37] 姜 晨,杨 波,范淑芳,等.中药干预腹膜透析肠功能障碍的疗效观察[J].天津中医药,2014,31(8):462-465.
[38] 梅 霞,唐 阁.从中西医结合角度浅述影响腹膜透析患者病死率的主要危险因素[J].天津中医药,2018,35(7):553-556.
[39] 李晓宁,吕 晶,郝亚宁.尿毒清颗粒对腹膜透析患者微炎症状态的影响[J].陕西中医,2014,35(6):688-689.
[40] 刘 曦,吴一帆,刘 惠,等.中医慢病管理对腹膜透析相关性腹膜炎发生率的影响[J].临床肾脏病杂志,2018,18(6):328-332.
[41] Coyne DW,Fleming R.Will targeting interleukin-6 in the anemia of CKD change our treatment paradigm?[J].Journal of the American Society of Nephrology,2021,32(1):6-8.

相似文献/References:

[1]魏晓菲,王晨丹.雷公藤甲素调控NLRP3/GSDMD/IL-1β途径改善六价铬对足细胞损伤的机制研究[J].陕西中医,2024,(9):1172.[doi:DOI:10.3969/j.issn.1000-7369.2024.09.004]
　WEI Xiaofei,WANG Chendan.Study on the mechanism of triptolide regulating NLRP3/GSDMD/IL-1β pathway to improve podocyte injury induced by Cr(Ⅵ)[J].,2024,(4):1172.[doi:DOI:10.3969/j.issn.1000-7369.2024.09.004]
[2]盛紫阳,栾仲秋,邓升华.苁蓉复肾方在抑制单侧输尿管梗阻大鼠肾间质纤维化中的应用及作用研究[J].陕西中医,2025,46(5):594.[doi:DOI:10.3969/j.issn.1000-7369.2025.05.004]
　SHENG Ziyang,LUAN Zhongqiu,DENG Shenghua.Application and effect of Congrong Fushen prescription on inhibiting renal interstitial fibrosis in rats with unilateral ureteral obstruction[J].,2025,46(4):594.[doi:DOI:10.3969/j.issn.1000-7369.2025.05.004]

备注/Memo

备注/Memo:
基金项目:国家自然科学基金资助项目(82174366)
更新日期/Last Update: 2023-04-10